Trade Sana Biotechnology, Inc. - SANA CFD

Trading Conditions

• Spread: 0.05
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 8.56
• Open: 8.21
• 1-Year Change: 65.86%
• Day's Range: 8.21 - 8.54

Sana Biotechnology, Inc. Company profile

About Sana Biotechnology Inc

Sana Biotechnology, Inc is a preclinical-stage biotechnology company. The Company is focused on creating and delivering engineered cells as medicines for patients. The Company develops in vivo and ex vivo cell engineering platforms for treatment across an array of therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system (CNS) disorders, cardiovascular diseases, and genetic disorders, among others. The Company’s process of repairing and controlling genes in the body, referred to as gene therapy or in vivo cell engineering, requires in vivo delivery of a therapeutic payload and modification of the genome. The Company’s fusogen technology in preclinical studies targets cell surface receptors when combined with delivery vehicles to form fusosomes and allows cell-specific delivery across multiple different cell types. It focuses this technology on delivering payloads to T cells, hepatocytes, and hematopoietic stem cells (HSCs).

Financial summary

BRIEF: For the nine months ended 30 September 2021, Sana Biotechnology Inc revenues was not reported. Net loss increased 42% to $245.2M. Higher net loss reflects Personnel increase of 36% to $55.2M (expense), General and administrative - Balancing increase of 80% to $32.6M (expense), Stock-based Compensation in R&D increase from $2.6M to $9.9M (expense).